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Abstract
            The Brugada disease, the last clinico-cardiologic entity described in the 20th century, 
initially called right bundle branch block syndrome with ST segment elevation from V1 to V2 or 
V3 and sudden cardiac death, is genetically determined in a dominant autosomal mode, and it 
affects the alpha subunit of the Na+ channel by alteration of chromosome 3 and mutation in the 
SCN5A gene.                                                                                                       
            In clinical diagnosis the mentioned electrocardiographic pattern in a patient without 
structural heart disease and positivity in pharmacological tests are considered major criteria. As 
minor criteria, the following are considered: positive family history, presence of syncope with 
unknown origin, documented episode of VT/VF, inducibility in electrophysiologic study and 
positivity of genetic study.                                                                                             
            The long-standing technology of ECG, with more than a century of existence, remains as 
the   supplementary   method   with   highest   value   in   diagnosis,   and   currently   new 
electrocardiographic   criteria   are   suggested,   which   indicate   high   risk   of   VF.  
            Natural history indicates a somber diagnosis in symptomatic patients with a high index of 
arrhythmic SCD secondary to very fast polymorphic ventricular tachycardia bursts, which 
degenerate into VF. Asymptomatic individuals with only a Brugada-type electrocardiographic 
pattern have a low risk. The prognosis seems to depend more on clinical facts, since a positive 
electrophysiologic study has an accuracy of just around 50%.                                               
            We propose that this entity should be promoted to the category of disease, since it has a 
characteristic set of signs and symptoms, and an identified genetic defect.                     
Preliminary Observations: "Prehistory"                                                                               
             Halfway through the 20th century (1953), Osher and Woff noticed the right bundle 
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branch block (RBBB) electrocardiographic pattern, associated to ST segment elevation in the 
right precordial leads. These were considered at the time as normal variants, not having been 
related to sudden cardiac death (SCD)1. In 1975, Calo2 reported an electrocardiographic triad 
that consisted of: R' wave, ST segment elevation and negative T wave in right precordial leads, 
which coincide with the characteristics of the electrocardiographic pattern currently known as 
Brugada-type, being considered a normal variant at the time.                                               
            During the 80s, the Center for Disease Control in Atlanta observed an abnormally high 
incidence of SCD in Asian refugees who immigrated to USA from the northeast of Thailand. 
This form of SCD is known in this country as Lai Tai (death during sleep). Approximately two 
decades later, the conclusion was reached that the entity known as "Sudden Unexplained 
Nocturnal Death Syndrome" (SUNDS) originates in an allele belonging to the same gene 
(SCN5A)   as   Brugada   Disease3.                                                                      
               In 1986, Prof. Pedro Brugada received his first patient with typical ECG, a Polish 
Caucasian child, who suffered several episodes of syncope. The boy presented as family 
background his sister's SCD, even though she had been treated with association of pacemaker 
implantation and amiodarone. In 1989, a patient with characteristic ECG was described as being 
a carrier of early repolarization syndrome4. In 1991, Pedro and Josep Brugada, adding 2 more 
cases, presented as an abstract in the NASPE meeting, a new clinical-cardiologic syndrome, 
typified by the association of RBBB, persistent ST segment elevation, normal QT interval and 
SCD5. 
Initial Observations And Chronological Evolution: "History"
            In 1992, the brothers from Catalonia (Spain), Pedro and Josep Brugada, presented the 
first description of the entity, adding four more patients to the initial description, making a total 
of eight6. This would be the last clinical-cardiologic entity to be identified in the 20th century7. 
One year later, Sumiyoshi et al8 identified the syndrome described by the Brugada brothers as 
being a variant of idiopathic ventricular fibrillation (IVF) and in the same year, Proclamer et al9 
described a case, posing the possibility of a new arrhythmic syndrome with the characteristics 
described by the Brugada brothers. In the same year, Italian authors from different centers said 
that the alleged new entity is just a minor initial form or concealed form of right ventricle 
arrhythmogenic dysplasia/cardiomyopathy 10,11. That same year, the Brugada brothers, in an 
Italian journal (G Ital Cardiol) replied to their colleagues from Padua and Nacarella, that they 
should not confuse issues, since in the new entity there is no underlying structural heart disease 
12.
            In 1994, Ferraccini et al13 reported a case of IVF associated to RBBB and ST segment 
elevation, and in the same year, Bjerregaard et al14 reported recurrent syncopes in a patient 
carrier of prominent J wave. In 1995, Tada et al15 pointed out the significance of ST segment 
elevation in right precordial leads in patients with IVF, and Tohyou et al  16  analyzed the 
incidence of RBBB with ST segment elevation in normal population. In this same year, 
D'Onofrio et al17 published an article wondering if the electrocardiographic pattern of RBBB 
associated to ST segment elevation from V1 to V3 in all the cases would correspond to a 
different   syndrome.                                                                                    
            In 1996, Gan-Xin Yan and Charles Antzelevitch18, in an article where they approached 
the cellular basis of J wave in ECG, used the eponym Brugada for the first time to describe the 
syndrome discovered four years earlier. That same year, Kobayashi et al19 called the typical 
electrocardiographic signs of the new entity as "Brugada type," and Miyazaki et al20, pointing 
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out to the autonomous modulation of ST segment elevation in patients with the syndrome 
described by the Brugada brothers, used the eponym just as Yan and Antzelevitch had done 
before. In the same year, Shimada also mentioned the eponym while reporting a case of the 
entity that presented monomorphic ventricular tachycardia (MVT)21. This is the first reference to 
a case of Brugada disease with MVT. In a short time, Dr. Bartolo Martini from the group of 
researchers from Padua claimed the paternity of the discovery, remarking that they had described 
the entity three years earlier, in 198922. In this work, the authors informed about the 
electrocardiographic manifestations as having a possible relationship with SCD; however, they 
concluded that in these cases there is a structural heart disease: right ventricle arrhythmogenic 
dysplasia/cardiomyopathy (RVAD), and did not acknowledge being in the presence of a new 
entity without an underlying organic substrate. Additionally, from the 6 patients mentioned in 
this article, only patient 3 presented the typical electrocardiographic pattern reported by the 
Brugada brothers  23,24.                                                                                          
            In 1996, Corrado et al25 presented the hypothesis of the existence of a subpopulation of 
RVAD that they called "concealed forms," which would present itself with the typical 
electrocardiographic   features   of   this   new   entity   proposed,   including   the   presence   of   a 
polymorphic form of ventricular tachycardia. In the same year, such authors as Ohe and Fontaine 
followed the same line, which later was proved to be wrong26,27. Nevertheless, the alterations of 
the vago-sympathetic autonomous tone only constituted a triggering factor, but would not be the 
cause   of   the   entity.                                                                                
            In 1997, Kobayashi et al 28 made the first description of the existence of an autonomous 
imbalance in Brugada disease, by means of the 123I-metaiodobenzylguanidine (MIBG) imaging 
techniques, which indicated the existence of a presynaptic autonomic dysfunction in the heart 29-
31. In 1997, Chinusi et al 32 made the first narration about the variable effect of disopiramide in 
ventricular arrhythmia induction in patients who are Brugada disease carriers, by acting on the 
Ito   channel,   sometimes   increasing   ST   segment   elevation,   and   possibly   normalizing   it.
            In 1998, the acknowledgment of Brugada disease as an entity became unquestionable 
when Chen et al33 identified three mutations in the SNC5A gene of chromosome 3p21-p24, 
which are responsible for Brugada disease and affect the alpha subunit of the Na+ channel. The 
mutations found were:
1) Missense or "wrong-information" mutation: this mutation affects exon 28, and in it, the amino 
acid glutamine is exchanged by leucine in codon 567 (L567Q) between domains I and II of the 
Na+ channel. This mutation determines a temporary increase in cation entrance during phase 
zero, with acceleration of recovery from the inactivation state.                                       
2) Structural of frameshift mutation: which consists in the subtraction of a nucleotide in the 
SCN5A   gene.                                                                                      
3) "Splice-donor" mutation: or mutation that accompanies the donor that affects intron 7 and 
introduces two bases of AA.
            The last two cause a failure in the channel operation. In the same year, and for the first 
time,  Nakamura  et  al34  showed  that the IC  class  antiarrhythmic agents, flecainide  and 
pilsicainide, may cause ST segment elevation in the inferior wall. Later, it would be verified that 
ST   segment   elevation   could   manifest   spontaneously   in   this   wall   in   Brugada   disease.  
            Makita et al35 demonstrated the importance of the "overlooked" accessory beta 1 subunit 
of the Na+ channel. Thus, the authors explained that an alteration related to the alpha/beta 
subunits influences on the functional state of the Na+ channel, by causing a higher overlapping 
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of   activation  and  inactivation  states,   giving  rise  to  a   window  current  in  T1620M  and 
consequently, in VF triggering. Dr. Tagaki et al36 described for the first time, employing an 
ultrafast computerized tomography, in 81% of a series of 26 patients, abnormalities in right 
ventricle wall motion, mostly located in the outflow tract (17 patients) or in inferior wall (4 
patients), wondering about the functional nature of this entity. 
Year 1999                                                                                                                 
            For the first time, Blazer et al37 included Brugada disease within the chapter of ion 
channel diseases or channelopathies. The authors showed that the affected channels in Brugada 
disease are primarily, the fast Na+ channel, and secondarily, the initial K+ outflow channel or 
Ito channel or transient outward current in phase 1 or 4-aminipyridine-sensitive channel, and 
slow Ca2+ inflow channel in phase 2 or L-type (“L-type slow or long-lasting” calcium channel 
ICa-L type ICa2+- L). In this year, Bezzina et al38 identified a single mutation in the Na+ 
channel, responsible for both Brugada disease and congenital long QT syndrome. In this way, 
the concept that both entities are allelic because they share the same locus was consolidated. 
Year 2000                                                                                                                           
            In this year, Dr. Takanori Ikeda et al39 identified the non-invasive markers of value in 
risk stratification in Brugada disease. The authors concluded that only high resolution ECG, and 
not QT interval dispersion or microvolt T wave alternans have value to identify the patients in 
high risk. They determined that high resolution ECG has a sensitivity of 89%, specificity of 
50%, positive predictive value of 70%, and negative predictive value of 77% for the presence of 
late potentials (LP). The authors did not find a correlation between the degree of ST segment 
elevation and the HV interval. One year later, the same group of researchers confirmed in JACC 
the previous results40. Dr. Silvia Priori et al41, in a prospective study of a numerous universe 
conducted with 52 families, arrived to the following conclusions:
1)asymptomatic individuals with Brugada-type electrocardiographic pattern, present a very low 
risk of SCD;
2)symptomatic with aborted SCD present a 23% of mortality rate in a mean 33-month follow-
up;
3)the genetic mutation can be identified in a 15% of the cases;
4)the positive electrophysiologic study has a 50% of accuracy;
5)pharmacological tests have only a 35% of accuracy in asymptomatic carriers.
Nishizaki et al42  showed the effect of insulin on ST segment elevation in this entity.  
Year 2001                                                                                                                                       
            In May, Dr. Ihor Gussak and Dr. Hammill developed the major and minor criteria for 
diagnosing this entity 43. The authors proposed that the presence of a major criterion and a minor 
one, constitute a diagnosis. They consider as major ones the electrocardiographic pattern in a 
patient without structural heart disease and positivity in pharmacological test; and as minor 
criteria the presence of positive family history, syncope of unknown origin, documented episode 
of VT/VF, inducibility in the electrophysiologic study, and positivity in genetic study (yet to be 
defined).
Year 2002                                                                                                                     
               In this year, genetic studies carried out by Vatta et al44  showed that unexplained 
nocturnal SCD syndrome, known as SUNDS (Sudden Unexplained Nocturnal Death Syndrome) 
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and Brugada disease are phenotypically, genetically and functionally identical and allelic since 
both affect the same gene: SCN5A. In November, the first virtual symposium about Brugada 
Syndrome was held (VIRTUAL SYMPOSIUM ABOUT THE BRUGADA SYNDROME: TEN 
YEARS OF HISTORY: 1992/2002) http://www.brugada-symposium.org/    45    , which achieved an 
extraordinary worldwide impact, where relevant issues related to this entity were updated by 
specialists of international level, having as Honorary Presidents Pedro, Josep and Ramon 
Brugada; as President of the Scientific Committee Dr. Andres Ricardo Perez Riera; and as 
President of the Steering Committee Dr. Edgardo Schapachnik. The event approached basic 
research, genetics, supplementary methods for diagnosis, electrophysiology; it showed for the 
first time a vectorcardiogram of this entity; guidelines were discussed regarding sports practice 
and   treatment.                                                                            
The material available was organized in Lectures written by the Members of the Honorary 
Committee, and articles written by the most distinguished specialists in the area, reports of cases, 
and a round table broadcast through radio via Internet. It is currently possible to access the 
symposium on the Internet: http://www.brugada-symposium.org/                                 
During the event, a change of category was proposed for this entity: from syndrome to disease, 
founded in that it meets the criteria that define a disease, i.e.: all conditions that affect animals or 
plants,   causing   an   interruption   or   modification   of   their   performance   as   a   response   to 
environmental factors, specific agents, genetic defects, or the combination of these, and when at 
least two of these criteria are present:
1)known etiologic agent;
2)identified genetic defect;
3)set of characteristic signs and symptoms or compatible anatomic alterations, or
4)a combination of the previous items.
Year   2003                                                                                  
            Atarashi et al46 suggested new electrocardiographic criteria that indicate high risk of VF 
in Brugada disease in a universe of 60 patients extracted from the Japanese register of Brugada 
syndrome. Thus, the authors established that:
1)S wave of duration = or > than 80msec in V1 has a predictive value of 40.5% and negative 
predictive value of 100% for VF with a 100% sensitivity;
2)ST segment elevation in V2 of 80msec or > measured from the J point has a positive 
predictive value of 37.8% and negative predictive value of 100% for VF with a 100% sensitivity. 
Both criteria are highly specific indicators for VF in this entity.
Conclusion
            We go through "pre-history" and history since 1953, when Osher and Woff noticed an 
electrocardiographic pattern that resembled an acute myocardial lesion, which they attributed to 
a normal variant associated to RBBB and ST segment elevation in the right precordial leads. The 
historical steps followed to relate this pattern with SCD are described in people frequently in a 
productive age in life, predominantly in males, and without verifiable structural heart disease.
            The original observation by the Spanish/Catalan Professor, Dr. Pedro Brugada in 1986, 
in a Pole caucasian and white child, with positive family background of SCD in a first-degree 
relative, ended in the initial description of the entity in 1992, called "A distinct clinical and 
electrocardiographic syndrome: right bundle branch block, persistent ST segment elevation with 
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normal QT interval and sudden cardiac death." The impact of the discovery was so important, 
that in a few years the eponym: Brugada Syndrome, was employed nearly unanimously, by most 
investigators.
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